Information Provided By:
Fly News Breaks for January 23, 2020
Jan 23, 2020 | 07:10 EDT
Cantor Fitzgerald analyst Alethia Young raised her price target for Incyte to $83 from $65 after adding adding ruxolitinib cream, which is being studied in atopic dermatitis, to her model. The analyst reiterates a Neutral rating on the shares. She thinks think the ruxolitinib pivotal study has a good possibility of working based on the Phase 2 data, with a clinical profile that could differentiate it from Eucrisa.
News For INCY From the Last 2 Days
Feb 16, 2020 | 15:57 EST
Specialty Pharma Analyst Chen, Biotech Analysts Young & Merle, along with Key Opinion Leaders Dr. Goldberg, Skin Laser & Surgery Specialists of NY & NJ and Dr. Weinberg, Forest Hills Dermatology Group, discuss the competitive landscape in atopic dermatitis at a Group Luncheon Meeting being held at Cantor's New York offices on February 24 at 12 pm.